<- Go Home
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. develops novel antibiotics. It provides XERAVA for the treatment of complicated intra-abdominal infections caused by susceptible microorganisms. The company was incorporated in 2006 and is based in Waltham, Massachusetts. Tetraphase Pharmaceuticals, Inc. operates as a subsidiary of La Jolla Pharmaceutical Company.
Market Cap
$16.1M
Volume
569.8K
Cash and Equivalents
$15.4M
EBITDA
-$48.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$21.4M
Profit Margin
259.11%
52 Week High
$8.60
52 Week Low
$0.56
Dividend
N/A
Price / Book Value
0.96
Price / Earnings
-0.29
Price / Tangible Book Value
1.28
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$49.2M
Return on Equity
175.72%
Return on Assets
-52.18
Cash and Short Term Investments
$15.4M
Debt
$4.7M
Equity
$16.6M
Revenue
$8.3M
Unlevered FCF
-$32.2M
Sector
Pharmaceuticals
Category
N/A